公开(公告)号：US10322097B2

公开(公告)日：2019-06-18

申请号：US14971153

申请日：2015-12-16

Applicant: Macau University of Science and Technology

Inventor： Kam Wai Wong ,  Yuen Kwan Law ,  Thomas Efferth ,  Su-Wei Xu ,  Sami Hamdoun ,  Liang Liu

IPC: A61K31/19 ,  A61K31/337 ,  A61K31/553 ,  A61K31/704 ,  A61K31/7048 ,  A61K33/24

Abstract: A quinonemethide triterpenoid is administered to subjects with multidrug-resistant cancer, in particular a cancer with enhanced expression and/or functional activity of ABC transporter proteins such as P-glycoprotein and/or an apoptosis-deficient, in particular p53-, Bax- or Bak-deficient, cancer, i.e. specific subgroups of subjects with cancer. The quinonemethide triterpenoid is suitable to treat cancer allowing for an accumulation of cytotoxic or therapeutic compounds in the cells while having exceptionally increased cytotoxic activity towards the multidrug-resistant cancer cells and while allowing for an increased activity of chemotherapeutic compounds. Methods for specifically targeting cancer cells with multidrug-resistance and methods for potentiating the activity of a chemotherapeutic compound in those cancer cells are also disclosed. A kit including a quinonemethide triterpenoid and a chemotherapeutic compound is also provided.

公开(公告)号：US09974766B2

公开(公告)日：2018-05-22

申请号：US14953860

申请日：2015-11-30

Applicant: Macau University of Science and Technology

Inventor： Kam Wai Wong ,  Yuen Kwan Law ,  Thomas Efferth ,  Onat Kadioglu ,  Liang Liu

IPC: A61K31/352 ,  A61K31/704 ,  A61K31/337

CPC classification number: A61K31/352 ,  A61K31/337 ,  A61K31/704 ,  A61K2300/00

Abstract: Prenylated isoflavones are suitable to specifically inhibit P-glycoprotein in multidrug-resistant cancer cells leading to an accumulation of cytotoxic compounds or therapeutic compounds in the cells while having exceptionally increased cytotoxic activity specifically towards multidrug-resistant cancer cells and while allowing for an increased activity of chemotherapeutic compounds towards which the cells are resistant.Also in accordance with the present invention is a method for specifically targeting cancer cells with multidrug-resistance as well as a method of potentiating the activity of a chemotherapeutic compound in multidrug-resistant cancer cells. In a further aspect, a kit including a prenylated isoflavone and a chemotherapeutic compound is provided.

公开(公告)号：US20170151212A1

公开(公告)日：2017-06-01

申请号：US14953860

申请日：2015-11-30

Applicant: Macau University of Science and Technology

Inventor： Kam Wai Wong ,  Yuen Kwan Law ,  Thomas Efferth ,  Onat Kadioglu ,  Liang Liu

IPC: A61K31/352 ,  A61K31/337 ,  A61K31/704

CPC classification number: A61K31/352 ,  A61K31/337 ,  A61K31/704 ,  A61K2300/00

Abstract: Prenylated isoflavones are suitable to specifically inhibit P-glycoprotein in multidrug-resistant cancer cells leading to an accumulation of cytotoxic compounds or therapeutic compounds in the cells while having exceptionally increased cytotoxic activity specifically towards multidrug-resistant cancer cells and while allowing for an increased activity of chemotherapeutic compounds towards which the cells are resistant.Also in accordance with the present invention is a method for specifically targeting cancer cells with multidrug-resistance as well as a method of potentiating the activity of a chemotherapeutic compound in multidrug-resistant cancer cells. In a further aspect, a kit including a prenylated isoflavone and a chemotherapeutic compound is provided.

公开(公告)号：US20170128394A1

公开(公告)日：2017-05-11

申请号：US14971153

申请日：2015-12-16

Applicant: Macau University of Science and Technology

Inventor： Kam Wai Wong ,  Yuen Kwan Law ,  Thomas Efferth ,  Su-Wei Xu ,  Sami Hamdoun ,  Liang Liu

IPC: A61K31/19 ,  A61K31/553 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/337 ,  A61K33/24

CPC classification number: A61K31/19 ,  A61K31/337 ,  A61K31/553 ,  A61K31/704 ,  A61K31/7048 ,  A61K33/24 ,  A61K2300/00

Abstract: A quinonemethide triterpenoid is administered to subjects with multidrug-resistant cancer, in particular a cancer with enhanced expression and/or functional activity of ABC transporter proteins such as P-glycoprotein and/or an apoptosis-deficient, in particular p53-, Bax- or Bak-deficient, cancer, i.e. specific subgroups of subjects with cancer. The quinonemethide triterpenoid is suitable to treat cancer allowing for an accumulation of cytotoxic or therapeutic compounds in the cells while having exceptionally increased cytotoxic activity towards the multidrug-resistant cancer cells and while allowing for an increased activity of chemotherapeutic compounds. Methods for specifically targeting cancer cells with multidrug-resistance and methods for potentiating the activity of a chemotherapeutic compound in those cancer cells are also disclosed. A kit including a quinonemethide triterpenoid and a chemotherapeutic compound is also provided.